^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NAV-006

i
Other names: NAV-006, NAV 006, RTX‑N109D
Associations
Trials
Company:
Navrogen
Drug class:
CD20 inhibitor
Related drugs:
Associations
Trials
almost3years
Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression. (PubMed, Oncol Lett)
Rituximab (RTX) is a CD20-targeting antibody that is the standard-of-care for patients with non-Hodgkin Lymphoma (NHL) cases. Furthermore, the study characterized an RTX variant, named NAV-006 (RTX-N109D), which was more refractory to the immunosuppressive effects mediated by CA125 as evidenced by its reduced CA125 interaction and increased activity of ADCC and CDC when compared with parent RTX. Taken together, these findings warranted further investigation on NAV-006 as a next generation anti-CD20 antibody that could improve the efficacy of parent RTX in NHL patients with high levels of CA125.
Journal
|
MUC16 (Mucin 16, Cell Surface Associated)
|
Rituxan (rituximab) • NAV-006